TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Verona Pharma's Ohtuvayre launch drives rapid growth and global expansion. Read about the VRNA stock's Q1 results, analyst ...

Verona Pharma (NASDAQ:VRNA)'s stock has reached an unprecedented peak, setting an all-time high at $56.49. This milestone underscores a remarkable period of growth for the $4.49 billion ...

Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential and bullish long-term outlook.

LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold an Investor Update in New York City ...

Verona Pharma (NASDAQ:VRNA) has observed the following analyst ratings within the last quarter: According to 6 analyst offering 12-month price targets in the last 3 months, Verona Pharma has an ...

Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company. The one-month return of Verona Pharma plc (NASDAQ:VRNA) was 23.24%, and its shares gained 350.61% of their value over the last 52 weeks.

Current Position of Verona Pharma Trading volume stands at 7,854,529, with VRNA's price up by 5.58%, positioned at $15.51. RSI indicators show the stock to be is currently neutral between ...

As of late, it has definitely been a great time to be an investor of Verona Pharma plc VRNA. The stock has moved higher by 69.9% in the past month, while it is also above its 20 Day SMA too. This ...

Verona, has ginned up strong numbers for its first launch. Of the $42 million in sales, $36 million came in the fourth quarter. Ohtuvayre was prescribed by 3,500 different healthcare professionals ...

Verona Pharma has clinched a $219 million deal to market its “first-in-class” drug, ensifentrine, targeting chronic obstructive pulmonary disease (COPD), in China.

Verona Pharma said on Thursday its therapy for a chronic and potentially fatal lung disease will have a wholesale price of $2,950 per month, above the estimated cost-effectiveness range by a drug ...